Steroid elimination within 24 hours after orthotopic liver transplantation: Effectiveness and tolerability

Hepatobiliary and Pancreatic Diseases International

Volumn 11, Issue 2, 2012, Pages 137-142

  Wu, Lin Wei ^a   Guo, Zhi Yong ^a   Tai, Qiang ^a   Ju, Wei Qiang ^a   Wang, Dong Ping ^a   Hu, An Bin ^a   Zhu, Xiao Feng ^a   He, Xiao Shun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Immunosuppression; Liver transplantation; Side effects; Steroid

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL INFECTION; CANCER RECURRENCE; CHINESE; COHORT ANALYSIS; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIQUEFACTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OSTEOPOROSIS; POSTOPERATIVE INFECTION; PROSPECTIVE STUDY; RISK; SURGICAL INFECTION; SURVIVAL; UNSPECIFIED SIDE EFFECT;

EID: 84859836033     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(12)60138-6     Document Type: Article

References (24)

1. Compston JE. Osteoporosis after liver transplantation. Liver Transpl 2003;9:321-330.
2. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75:SS3-24.
3. Stegall MD, Everson GT, Schroter G, Karrer F, Bilir B, Sternberg T, et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology 1997;25:173-177.
4. Stockmann M, Steinmuller T, Nolting S, Neuhaus P. Posttransplant diabetes mellitus after orthotopic liver transplantation. Transplant Proc 2002;34:1571-1572.
5. Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl 2003;9:587-595.
6. Pageaux GP, Calmus Y, Boillot O, Ducerf C, Vanlemmens C, Boudjema K, et al. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl 2004;10:1454-1460.
7. Washburn K, Speeg KV, Esterl R, Cigarroa F, Pollack M, Tourtellot C, et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. Transplantation 2001;72:1675-1679.
8. Pirenne J, Aerts R, Koshiba T, Van Gelder F, Roskams T, Schetz M, et al. Steroid-free immunosuppression during and after liver transplantation--a 3-yr follow-up report. Clin Transplant 2003;17:177-182.
9. Guckelberger O, Mutzke F, Glanemann M, Neumann UP, Jonas S, Neuhaus R, et al. Validation of cardiovascular risk scores in a liver transplant population. Liver Transpl 2006;12: 394-401.
10. Matinlauri IH, Nurminen MM, Hockerstedt KA, Isoniemi HM. Changes in liver graft rejections over time. Transplant Proc 2006;38:2663-2666.
11. Moench C, Barreiros AP, Schuchmann M, Bittinger F, Thiesen J, Hommel G, et al. Tacrolimus monotherapy without steroids after liver transplantation--a prospective randomized double-blinded placebo-controlled trial. Am J Transplant 2007;7:1616-1623.
12. Toyoki Y, Hakamada K, Narumi S, Totsuka E, Nara M, Ono H, et al. Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation: a singlecenter experience. Transplant Proc 2004;36:2279-2281.
13. Hu AB, He XS, Wu ZP, Zhu XF, Ma Y, Wang DP, et al. Evaluation of efficacy and safety on steroid withdraw at the seventh day after liver transplantation. Zhonghua Wai Ke Za Zhi 2008;46:1126-1128.
14. Langrehr JM, Glanemann M, Guckelberger O, Klupp J, Neumann U, Machens C, et al. A randomized, placebocontrolled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation. Clin Transplant 1998;12:303-312.
15. Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, et al. Basiliximab (Simulect) for the treatment of steroidresistant rejection in pediatric liver transpland recipients: a preliminary experience. Transplantation 2003;75:796-799.
16. Lee KH, Da Costa M, Lim SG, Tan KC. Delayed tacrolimus is safe with basiliximab induction therapy. Liver Transpl 2002; 8:732.
17. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-142.
18. Ringe B, Braun F, Schutz E, Fuzesi L, Lorf T, Canelo R, et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001;71:508-515.
19. Vivarelli M, Burra P, La Barba G, Canova D, Senzolo M, Cucchetti A, et al. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007;47:793-798.
20. Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab+steroids or basiliximab+placebo, in addition to cyclosporine and azathioprine. Transplantation 2004;78:1488-1495.
21. Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004;78:966-971.
22. Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004;10:728-733.
23. John PR, Thuluvath PJ. Outcome of liver transplantation in patients with diabetes mellitus: a case-control study. Hepatology 2001;34:889-895.
24. Desai S, Hong JC, Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver Int 2010;30:948-957.